预约演示
更新于：2026-05-25
Olodaterol Hydrochloride/Tiotropium Bromide
噻托溴铵奥达特罗
更新于：2026-05-25
概要
基本信息
药物类型 小分子化药 |
别名 BI-1744-CL/tiotropium bromide、Olodaterol Hydrochloride/Tiotropium Bromide Hydrate、Olodaterol/tiotropium bromide + [16] |
作用方式 拮抗剂、激动剂 |
作用机制 M3 receptor拮抗剂(毒蕈碱型乙酰胆碱受体M3拮抗剂)、β2-adrenergic receptor激动剂(β2-肾上腺素能受体激动剂) |
最高研发阶段批准上市 |
首次获批日期 美国 (2015-05-21), |
最高研发阶段(中国)无进展 |
特殊审评优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C21H27ClN2O5 |
InChIKeyKCEHVJZZIGJAAW-FERBBOLQSA-N |
CAS号869477-96-3 |
查看全部结构式(2)
关联
60
项与 噻托溴铵奥达特罗 相关的临床试验CTR20253032
噻托溴铵奥达特罗吸入喷雾剂在健康参与者中随机、开放、两制剂、两周期交叉、空腹状态下的生物等效性试验
CTR20243725
评估受试制剂噻托溴铵奥达特罗吸入喷雾剂与参比制剂噻托溴铵奥达特罗吸入喷雾剂（思合华®能倍乐®）作用于健康成年受试者的单中心、开放、随机、单剂量、交叉生物等效性研究
CTR20233863
噻托溴铵奥达特罗吸入喷雾剂在中国成年健康受试者中的一项随机、开放、空腹单次给药、交叉生物等效性试验
100 项与 噻托溴铵奥达特罗 相关的临床结果
登录后查看更多信息
100 项与 噻托溴铵奥达特罗 相关的转化医学
登录后查看更多信息
100 项与 噻托溴铵奥达特罗 相关的专利（医药）
登录后查看更多信息
154
项与 噻托溴铵奥达特罗 相关的文献（医药）2026-04-01JAMA Internal Medicine
Comparative Effectiveness and Safety of LAMA-LABA Inhalers in Chronic Obstructive Pulmonary Disease
Article
作者: Wang, Shirley V. ; Suissa, Samy ; Feldman, William B. ; Portela, Gerard T.
Importance:
Dual bronchodilator therapy with a long-acting muscarinic antagonist (LAMA) and a long-acting β
2
-agonist (LABA) is recommended for most patients with symptomatic chronic obstructive pulmonary disease (COPD). Fixed-dose LAMA-LABA therapies are available in metered-dose, dry powder, and soft mist inhalers. However, metered-dosed inhalers are associated with greater greenhouse gas emissions than either dry powder or soft mist inhalers, and questions persist about potential intraclass differences among LAMA-LABAs given variability in their active ingredients, dosing schedules, and delivery devices.
Objective:
To evaluate the comparative effectiveness and safety of once-daily umeclidinium-vilanterol dry powder inhalers, twice-daily glycopyrrolate-formoterol metered-dosed inhalers, and once-daily tiotropium-olodaterol soft mist inhalers.
Design, Setting, and Participants:
This observational active-comparator study analyzed claims of patients (≥40 years) newly treated with LAMA-LABA inhalers and continuously enrolled in a large commercial health insurance or Medicare Advantage plan during the 183-day baseline period. Patients were propensity score matched 1:1 into 3 cohorts with index dates ranging from May 1, 2016, to February 28, 2025. Data were analyzed from July to August 2025.
Exposures:
Patients treated with umeclidinium-vilanterol, glycopyrrolate-formoterol, or tiotropium-olodaterol fixed-dose inhalers.
Main Outcomes and Measures:
Time to the first moderate or severe COPD exacerbation, major adverse cardiovascular event, urinary tract infection, and pneumonia hospitalization.
Results:
The cohorts included 9479 matched pairs of patients receiving umeclidinium-vilanterol vs glycopyrrolate-formoterol (mean age, 68.9 [SD, 9.0] years; 10 319 women [54.4%]; 8636 men [45.6%]), 9598 receiving tiotropium-olodaterol vs glycopyrrolate-formoterol (mean age, 69.2 [SD, 8.7] years; 10 513 women [54.8%]; 8680 men [45.2%]), and 36 740 receiving umeclidinium-vilanterol vs tiotropium-olodaterol (mean age, 71.5 [SD, 8.4] years; 39 429 women [53.7%]; 34 044 men [46.3%]). Umeclidinium-vilanterol was associated with a 14% lower hazard of a first moderate or severe COPD exacerbation than glycopyrrolate-formoterol (hazard ratio [HR], 0.86; 95% CI, 0.81-0.91; number needed to treat [NNT], 17) and was associated with a 3% lower hazard than tiotropium-olodaterol (HR, 0.97; 95% CI, 0.94-0.99; NNT, 100). Tiotropium-olodaterol was associated with a 6% lower hazard of a first moderate or severe COPD exacerbation than glycopyrrolate-formoterol (HR, 0.94; 95% CI, 0.89-1.00). Similar risks of first major adverse cardiovascular event, urinary tract infection, and pneumonia hospitalization were observed among patients in all 3 cohorts.
Conclusions and Relevance:
This cohort study found that umeclidinium-vilanterol was associated with improved clinical outcomes compared with glycopyrrolate-formoterol and tiotropium-olodaterol. Patients, prescribers, and health systems may consider once-daily umeclidinium-vilanterol dry powder inhalers over alternatives among new users of LAMA-LABA therapy.
2024-08-08Expert review of pharmacoeconomics & outcomes research
Improved medication adherence in COPD patients using tiotropium or tiotropium olodaterol with the HealthPrize digital behavior change program
Article
作者: DeKoven, Mitchell ; Shaikh, Asif ; Firlik, Katrina S ; Anupindi, Vamshi Ruthwik ; Firlik, Katrina S. ; Hayes, Vincent ; Franchino-Elder, Jessica
OBJECTIVE:
To assess the impact of the HealthPrize RespiPoints™ program on treatment adherence and persistence in adults with chronic obstructive pulmonary disease (COPD).
METHODS:
In this retrospective cohort study, program participants and nonparticipants receiving tiotropium bromide (TIO) or TIO and olodaterol between 1 January 2015-31 March 2020 were propensity score matched (PSM), from the linked database of the HealthPrize patient list and IQVIA PharMetrics® Plus. Treatment adherence, persistence, healthcare resource utilization, and costs were compared. Multivariable logistic regression models assessed the odds of adherence (≥80% proportion of days covered [PDC]), adjusted risk of discontinuation, and adjusted total healthcare costs.
RESULTS:
Program participants (n = 262) demonstrated a 44% greater adherence during followup than nonparticipants (n = 262) (mean [standard deviation] PDC: 0.72 [0.27] vs 0.50 [0.36], p < 0.0001). Participants had higher odds of adherence vs nonparticipants (adjusted odds ratio: 2.51; 95% confidence interval: 1.72-3.66, p < 0.0001) and a lower percentage of participants discontinued their index medication (19.85% vs 33.59%, p = 0.0004). Fewer participants were hospitalized during follow-up (13.74% vs 17.56%, p = 0.23); adjusted total medical costs were 24% lower (p = 0.08). Higher pharmacy costs partially offset lower healthcare costs.
CONCLUSIONS:
Program participants showed improved COPD medication adherence and persistence compared to nonparticipants.
2023-08-03Expert opinion on drug delivery
Advances in soft mist inhalers
Review
作者: Traini, D. ; Muellinger, Bernhard ; Wong, Chun Yuen Jerry ; Sibum, Imco ; Buchmann, Nicolas A. ; Ong, Hui Xin ; Komalla, Varsha ; Chaugule, Vishal ; Nijdam, Wietze ; Soria, Julio
INTRODUCTION:
Soft mist inhalers (SMIs) are propellant-free inhalers that utilize mechanical power to deliver single or multiple doses of inhalable drug aerosols in the form of a slow mist to patients. Compared to traditional inhalers, SMIs allow for a longer and slower release of aerosol with a smaller ballistic effect, leading to a limited loss in the oropharyngeal area, whilst requiring little coordination of actuation and inhalation by patients. Currently, the Respimat® is the only commercially available SMI, with several others in different stages of preclinical and clinical development.
AREAS COVERED:
The primary purpose of this review is to critically assess recent advances in SMIs for the delivery of inhaled therapeutics.
EXPERT OPINION:
Advanced particle formulations, such as nanoparticles which target specific areas of the lung, Biologics, such as vaccines, proteins, and antibodies (which are sensitive to aerosolization), are expected to be generally delivered by SMIs. Furthermore, repurposed drugs are expected to constitute a large share of future formulations to be delivered by SMIs. SMIs can also be employed for the delivery of formulations that target systemic diseases. Finally, digitalizing SMIs would improve patient adherence and provide clinicians with fundamental insights into patients' treatment progress.
100 项与 噻托溴铵奥达特罗 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 慢性支气管炎 | 日本 | 2015-11-18 | |
| 肺气肿 | 日本 | 2015-11-18 | |
| 慢性阻塞性肺疾病 | 美国 | 2015-05-21 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 慢性肺疾病 | 临床3期 | 美国 | 2014-03-01 | |
| 慢性肺疾病 | 临床3期 | 澳大利亚 | 2014-03-01 | |
| 慢性肺疾病 | 临床3期 | 奥地利 | 2014-03-01 | |
| 慢性肺疾病 | 临床3期 | 比利时 | 2014-03-01 | |
| 慢性肺疾病 | 临床3期 | 加拿大 | 2014-03-01 | |
| 慢性肺疾病 | 临床3期 | 丹麦 | 2014-03-01 | |
| 慢性肺疾病 | 临床3期 | 德国 | 2014-03-01 | |
| 慢性肺疾病 | 临床3期 | 新西兰 | 2014-03-01 | |
| 慢性肺疾病 | 临床3期 | 波兰 | 2014-03-01 | |
| 慢性肺疾病 | 临床3期 | 葡萄牙 | 2014-03-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | Tiotropium/Olodaterol (TIO + OLO) | 選廠網製顧鹽願憲構壓(願顧憲製衊鹽壓醖餘鏇) = 鬱積繭壓衊網築窪鹹築 糧廠繭餘鹹獵網衊糧餘 (範醖觸憲蓋壓壓願鏇衊, 0.86 ~ 1.0) | - | 2023-07-01 | ||
N/A | 1,255 | 廠衊構膚淵獵遞鏇構糧(製蓋壓遞選顧積艱範鏇) = 積餘選選壓窪範鏇襯鏇 製獵簾選襯鏇襯繭繭構 (築鹹簾選糧選襯窪衊衊 ) 更多 | - | 2022-08-10 | |||
临床4期 | 14 | 鹽鹹築淵齋醖積衊憲淵(築窪醖蓋願夢遞築鹹蓋) = 選願顧齋鑰觸齋憲鏇繭 鹹簾糧製膚衊壓範襯獵 (顧餘鹹蓋築淵糧齋窪鹹 ) | 不佳 | 2022-03-24 | |||
Placebo | 鹽鹹築淵齋醖積衊憲淵(築窪醖蓋願夢遞築鹹蓋) = 醖壓襯繭築齋餘鑰願蓋 鹹簾糧製膚衊壓範襯獵 (顧餘鹹蓋築淵糧齋窪鹹 ) | ||||||
临床4期 | 714 | LABA (Long-Acting Beta Agonist) (Triple therapy) | 築蓋積艱夢廠觸夢獵範(鹽鹽醖鏇壓鹹壓夢鬱獵) = 廠選鏇鹹鹽醖艱鬱夢網 簾餘願餘糧艱獵築壓構 (製築製範築網夢範膚範, 願鏇積窪選範願窪鹽壓 ~ 憲製獵廠餘鏇齋鏇鹽願) 更多 | - | 2021-12-09 | ||
临床4期 | 213 | Olo+Tio (Tio+Olo (5μg/5μg) - Sub-optimal PIFR) | 淵願鑰簾憲餘蓋觸觸憲(顧網範構襯衊齋鏇壓壓) = 襯壓艱鑰鬱簾襯網鬱蓋 膚夢選糧襯願壓襯膚憲 (蓋鑰蓋積鬱齋醖積襯淵, 0.033) 更多 | - | 2021-11-18 | ||
Placebo (Matching Placebo - Sub-optimal PIFR) | 淵願鑰簾憲餘蓋觸觸憲(顧網範構襯衊齋鏇壓壓) = 鹹繭餘鬱繭淵觸選壓餘 膚夢選糧襯願壓襯膚憲 (蓋鑰蓋積鬱齋醖積襯淵, 0.031) 更多 | ||||||
N/A | 1,322 | 鏇襯糧簾範廠遞顧築選(蓋淵簾壓壓鬱膚憲構獵) = 鑰網繭鏇廠製壓壓壓餘 蓋鑰窪鑰餘膚築鬱網鹹 (構憲觸艱網構齋網範窪 ) 更多 | - | 2021-07-01 | |||
N/A | 慢性阻塞性肺疾病 维持 | 42,953 | 製襯艱鏇網顧憲獵築選(壓積壓糧壓膚鏇網製鏇): adjusted hazard ratio = 0.76 (95% CI, 0.68 ~ 0.85) 更多 | 积极 | 2021-03-15 | ||
LABA/ICS | |||||||
临床3期 | 2,055 | 醖廠壓膚簾蓋餘醖糧獵(膚壓窪壓糧獵夢壓鏇窪): HR = 0.76 (95% CI, 0.68 ~ 0.85) | 积极 | 2021-01-01 | |||
N/A | - | 範繭壓壓鬱憲顧窪憲繭(醖鹽膚糧願鬱鹽蓋製憲) = 窪艱網廠廠窪齋醖築淵 鏇蓋選構鑰觸窪淵範艱 (簾網憲構簾顧遞窪簾醖, 0.033 ~ 0.115) | - | 2020-08-01 | |||
临床4期 | 14 | Placebo Respimat+Stiolto Respimat (Stiolto Respimat) | 鹽廠築襯製淵淵醖遞餘(膚鑰齋繭壓簾網網醖範) = 顧廠夢襯網淵餘獵繭繭 製範淵範壓顧簾蓋鹹鏇 (糧構鏇遞選築蓋憲範願, 鹽選繭選窪蓋鬱遞顧襯 ~ 窪糧糧積鬱壓顧醖鑰鏇) 更多 | - | 2020-06-16 | ||
Placebo Respimat+Stiolto Respimat (Placebo Respimat) | 鹽廠築襯製淵淵醖遞餘(膚鑰齋繭壓簾網網醖範) = 鏇網築網淵夢築衊簾鬱 製範淵範壓顧簾蓋鹹鏇 (糧構鏇遞選築蓋憲範願, 鹽夢構廠壓築顧夢襯遞 ~ 鏇餘繭選餘繭積艱齋選) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用